Skip to Content

AlloMek History

AlloMek Therapeutics was formed to develop, and out-license, a novel class of MEK inhibitors represented by the lead compound CIP-137401.

CIP-1374 was discovered by Cheminpharma, LLC team. All intellectual property and rights related to CIP-1374 were transferred from Cheminpharma to AlloMek Therapeutics.

AlloMek Therapeutics was founded by two share holders:

Uday Khire, PhD
Barry Hart, PhD

Initial Investment: Cash and Research Support: Robert Wolfe, PhD, Integral BioSciences
AlloMek Business Model: AlloMek is a virtual company that relies on high quality Contract Research Organizations to execute experiments to further the development of its MEK program.